Clinical Trial Update: HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating HR070803 in combination with oxaliplatin and 5-FU/leucovorin versus AG for first-line treatment of advanced pancreatic cancer; currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil/Leucovorin (5-FU/leucovorin)
• HR070803
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: First-line Treatment of Advanced Pancreatic Cancer | Phase 3 | Status: RECRUITING